ESMO 2021: PRIMORDIUM – A Randomized, International, Trial-in-Progress of Adding Apalutamide to Radiotherapy and an LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Boris Hadaschik presented on the trial in progress, PRIMORDIUM (NCT04557059).